Abstract
HUDSON (NCT03334617) is a multi-arm umbrella trial for patients with advanced non-small-cell lung cancer (NSCLC) previously treated with platinum-doublet chemotherapy and anti-PD-(L)1 immunotherapy (separately or in combination) who had disease progression on prior anti-PD-(L)1 therapy. The study evaluates the efficacy, safety, and tolerability of multiple treatment combinations tailored by molecular alteration, with the goal of overcoming resistance to PD-(L)1 blockade. Here we present mature efficacy and safety results for the initial combinations - durvalumab plus: olaparib (PARP inhibitor; Module 1), danvatirsen (STAT3 inhibitor; Module 2), ceralasertib (ATR inhibitor; Module 3), and oleclumab (anti-CD73 antibody; Module 5).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
